

Spevigo (spesolimab-sbzo) Effective 04/01/2023

Plan	✓ MassHealth UPPL☐ Commercial/Exchange		⊠ Prior Authorization
Benefit	☑ Pharmacy Benefit☑ Medical Benefit (NLX)	Program Type	☐ Quantity Limit☐ Step Therapy
Specialty	This medication has been designated specialty and must be filled at a contracted		
Limitations	specialty pharmacy when obtained through the pharmacy benefit.		
	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
Contact	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
Information	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Spevigo®(spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.

Coverage Guidelines

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

- 1. Diagnosis of Generalized Pustular Psoriasis (GPP) flare
- 2. Member is ≥18 years of age
- 3. Appropriate dosing

Limitations

1. Approvals will be granted for up to 2 doses (given at least a week apart)

References

- 1. Spevigo®[package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc.; 2022 Jun.
- FDA Approves Spevigo for Treatment of Generalized Pustular Psoriasis Flares in Adults [press release on the internet]. PharmacyTimes; 2022 Sep 12 [cited 2022 Sep 17]. Available from: https://www.pharmacytimes.com/view/fda-approves-spevigo-for-treatment-of-generalized-pustularpsoriasis-flares-in-adults.

Review History

Reviewed and created for P&T. Matched MH UPPL criteria to be in compliance with Masshealth unified formulary requirements. Effective 4/1/23.

Mass General Brigham Health Plan includes Mass General Brigham Health Plan, Inc. and Mass General Brigham Health Insurance Company.